OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Grajales-Cruz on Real-World Teclistamab Data in BCMA-Pretreated Multiple Myeloma

April 4th 2024

Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.

Dr Petrylak on Emerging Therapeutic Targets in Urothelial Cancer

April 4th 2024

Daniel Petrylak, MD, discusses emerging therapeutic targets showing early potential in metastatic urothelial cancer.

Dr Kareff on the Utility of ADCs in NSCLC

April 4th 2024

Samuel Kareff, MD, MPH, discusses the treatment of patients with non–small cell lung cancer.

Dr Nanda on Neoadjuvant Treatment in HER2+ Breast Cancer

April 4th 2024

Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.

Dr Ip on the Implications of NGS Plus Machine Learning for Diagnosing Hematologic Malignancies

April 4th 2024

Andrew Ip, MD, discusses the implications of using next-generation sequencing alongside machine learning in the diagnosis of hematologic malignancies.

Dr Petrylak on Treatment With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

April 4th 2024

Daniel Petrylak, MD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

Dr Nooka on the Utility of Iopofosine I 131 in Waldenström Macroglobulinemia

April 3rd 2024

Ajay K. Nooka, MD, MPH, FACP, discusses the CLOVER-WaM trial of iopofosine I 131 for heavily pretreated, refractory Waldenström macroglobulinemia.

Dr Arteaga on CDK4/6 Inhibitor Resistance in ER+ Breast Cancer

April 3rd 2024

Carlos Arteaga, MD, discusses the resistance to CDK4/6 inhibitors in estrogen receptor–positive breast cancer.

Dr Patel on the Utility of Orca-T in Hematologic Malignancies

April 3rd 2024

Sagar Patel, MD, discusses the utility of the Orca-T platform in patients with hematologic malignancies, highlighting the platform's safety.

Dr Leal on the Utility of Patritumab Deruxtecan in EGFR+ NSCLC

April 3rd 2024

Ticiana Leal, MD, discusses the investigation of patritumab deruxtecan in the HERTHENA-Lung01 study in advanced EGFR-mutated non–small cell lung cancer.

Dr Jha on Community Accrual to the ECLIPSE Trial in Prostate Cancer

April 3rd 2024

Gautam Jha, MD, discusses collaborative efforts between community and academic oncologists to accrue patients to the ECLIPSE trial.

Dr Creelan on the Promise of Cemiplimab in Squamous NSCLC

April 3rd 2024

Ben Creelan, MD, discusses survival outcomes with cemiplimab in patients with squamous non–small cell lung cancer.

Drs Antonarakis and Jha on Extending Clinical Trials to the Community Setting

April 3rd 2024

Emmanuel Antonarakis, MD, and Gautam Jha, MD, on collaboration efforts extending the reach of clinical trials beyond university hospitals.

Dr Stintzing on the Safety Profile of Fruquintinib in mCRC

April 2nd 2024

Sebastian Stintzing, MD, discusses the Q-TWiST analysis of fruquintinib plus best supportive care in metastatic colorectal cancer.

Dr Zamarin on Recent Updates in Endometrial Cancer

April 2nd 2024

Dmitriy Zamarin, MD, PhD, discusses the most recent advances in gynecologic cancer management, particularly in endometrial cancer.

Dr Spiegel on the Challenges Associated With CAR T-Cell Therapy in Solid Tumors

April 2nd 2024

Jay Spiegel, MD, discusses some of the challenges of using CAR T-cell therapy in patients with solid tumors.

Dr Spratt on Uncertainties Regarding Treatment Intensification in High-Risk Prostate Cancer

April 1st 2024

Daniel Spratt, MD, discusses ongoing debate and uncertainties regarding the optimal use of treatment intensification in high-risk prostate cancer.

Dr Pedersen on the Evolution of Immunotherapy in HCC

April 1st 2024

Katrina S. Pedersen, MD, MS, discusses the evolution of the role of immunotherapy in the treatment of patients with hepatocellular carcinoma.

Dr Mahtani on Addressing Unmet Needs in Breast Cancer

April 1st 2024

Reshma L. Mahtani, DO, discusses how attempts to address unmet needs in breast cancer have evolved over time.

Dr Chudgar on Resection Eligibility in NSCLC

April 1st 2024

Neel P. Chudgar, MD, discusses considerations for determining lung cancer resection eligibility and how neoadjuvant therapy may affect resectability.